NDA 019574 · Casper Pharma LLC
Thalitone
Chlorthalidone · Oral · Thiazide-like Diuretic
Last checked: Nov 19, 2026Latest source record: Sep 17, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1988
Dec 20, 1988
Approved uses
1
Original approval plus efficacy supplements
Registered trials
92
39 Phase 3, 5 recruiting
FAERS reports
11,770
7,408 serious, 704 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 25, 2026.
THALITONE is a thiazide-like diuretic indicated: • For the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). • as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome (1.2). 1.1 Hypertension THALITONE ® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with THALITONE. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely...
Mechanism: Chlorthalidone is a long-acting oral diuretic with antihypertensive activity. The diuretic effects of chlorthalidone and the benzothiadiazine (thiazide) diuretics appear to arise from similar mechanisms and the maximal effect of chlorthalidone and the thiazides appear to be similar. The site of the action appears to be the distal convoluted tubule of the nephron. Although the mechanism of action of chlorthalidone and related drugs is not wholly clear, sodium and water depletion appear to provide a basis for its antihypertensive effect.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 20, 1988 Original approval · Type 3 - New Dosage Form
2 products under this application
- THALITONE · CHLORTHALIDONE 15MG · TABLET, ORAL · Prescription
- THALITONE · CHLORTHALIDONE 25MG · TABLET, ORAL · Discontinued · TE BX
Clinical trials
Interventional ClinicalTrials.gov studies with "Chlorthalidone" as an intervention, any sponsor and status, largest first.
- Diuretic Comparison ProjectPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT02185417 · 20,723 participants · Start Jun 15, 2016 · Primary completion Oct 15, 2022
Drug: Hydrochlorothiazide (HCTZ); Chlorthalidone (CTD) · For: Hypertension
Sites: Birmingham, Alabama; Anchorage, Alaska; Fayetteville, Arkansas · 70 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Coronavirus (COVID-19) ACEi/ARB InvestigationPivotal-lookingSuspended
National University of Ireland, Galway, IrelandAcademic, hospital or other
NCT04330300 · 2,414 participants (planned) · Start Apr 30, 2020 · Primary completion Jul 31, 2021
Drug: Thiazide or Thiazide-like diuretics; Calcium Channel Blockers and 2 more · For: Hypertension; COVID-19
Sites: Galway, Ireland
- Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe HypertensionPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00847626 · 1,711 participants · Start Jan 2009 · Primary completion May 2010
Drug: Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone and 9 more · For: Hypertension
Sites: Birmingham, Alabama; Columbiana, Alabama; Tuscaloosa, Alabama · 99 sites in all
- Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe HypertensionPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00846365 · 1,085 participants · Start Mar 2009 · Primary completion Jun 2010
Drug: Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone and 1 more · For: Essential Hypertension
Sites: Birmingham, Alabama; Haleyville, Alabama; Hueytown, Alabama · 80 sites in all
- Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT01033071 · 1,071 participants · Start Jan 2010 · Primary completion Oct 2010
Drug: Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone and 1 more · For: Essential Hypertension
Sites: Gulf Shores, Alabama; Litchfield Park, Arizona; Mesa, Arizona · 94 sites in all
- Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and DiabetesPivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT01368536 · 975 participants · Start May 2011 · Primary completion Feb 2012
Drug: Valturna; Amlodipine and 3 more · For: Hypertension; Stage 2 Hypertension; Diabetes
Sites: Athens, Alabama; Florence, Alabama; Huntsville, Alabama · 97 sites in all
- Comparison of Optimal Hypertension RegimensPivotal-lookingCompleted
Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
NCT02847338 · 940 participants · Start Nov 2016 · Primary completion Oct 2023
Drug: Amlodipine; Lisinopril and 2 more · For: Hypertension
Sites: Cambridge, United Kingdom; Birmingham, United Kingdom; Cardiff, United Kingdom · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue919
- nausea758
- drug ineffective756
- diarrhoea700
- dizziness598
- pain569
- off label use564
- headache557
- dyspnoea536
- acute kidney injury476
- chronic kidney disease461
- arthralgia457
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 40 |
| 2006 | 61 |
| 2007 | 44 |
| 2008 | 68 |
| 2009 | 88 |
| 2010 | 128 |
| 2011 | 171 |
| 2012 | 215 |
| 2013 | 224 |
| 2014 | 344 |
| 2015 | 535 |
| 2016 | 671 |
| 2017 | 615 |
| 2018 | 785 |
| 2019 | 953 |
| 2020 | 887 |
| 2021 | 954 |
| 2022 | 1,064 |
| 2023 | 1,009 |
| 2024 | 1,056 |
| 2025 | 1,135 |
| 2026 | 691 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Thalitone (Chlorthalidone)
2024 spending
$578K
Beneficiaries
1,493
3,517 claims
Per beneficiary
$387
$3.56 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $12,930 |
| 2022 | $312,224 |
| 2023 | $538,436 |
| 2024 | $578,075 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
· JAMA 2002 · Clinical Trial, Comparative Study
- Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Ishani A, Cushman WC, Leatherman SM, et al. · N Engl J Med 2022 · Comparative Study, Pragmatic Clinical Trial
- Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.
Agarwal R, Sinha AD, Cramer AE, et al. · N Engl J Med 2021 · Multicenter Study, Randomized Controlled Trial
- Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects.
Roush GC, Ernst ME, Kostis JB, et al. · Hypertension 2015 · Meta-Analysis, Systematic Review
- New wrinkles in hypertension management 2022.
Carey RM, Whelton PK · Curr Opin Cardiol 2022 · Meta-Analysis, Review
- Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial.
Webster R, Salam A, de Silva HA, et al. · JAMA 2018 · Comparative Study, Multicenter Study
Sponsor: Casper Pharma LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.